Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adverse Events Reporting System Needs Immediate Upgrade – FDA Consultant

This article was originally published in The Tan Sheet

Executive Summary

FDA should resume an abandoned plan for software acquisition and "immediately" begin the process of upgrading Center for Drug Evaluation and Research's Adverse Events Reporting System, a consultant hired by the agency recommends in a report that is highly critical of the center's efforts to create a second-generation AERS

You may also be interested in...



FDA Needs Information Technology Strategic Plan, GAO Recommends

FDA has at least 16 projects under way to improve its information technology systems and infrastructure, but no comprehensive IT strategic plan to coordinate and manage the efforts, according to the Government Accountability Office

FDA Needs Information Technology Strategic Plan, GAO Recommends

FDA has at least 16 projects under way to improve its information technology systems and infrastructure, but no comprehensive IT strategic plan to coordinate and manage the efforts, according to the Government Accountability Office

FDA Needs Information Technology Strategic Plan, GAO Recommends

FDA has at least 16 projects under way to improve its information technology systems and infrastructure, but no comprehensive IT strategic plan to coordinate and manage the efforts, according to the Government Accountability Office

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100286

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel